Annual report pursuant to Section 13 and 15(d)

16. Supplemental Disclosure of Cash Flow Information (Details)

v3.7.0.1
16. Supplemental Disclosure of Cash Flow Information (Details) - USD ($)
2 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2016
Supplemental Cash Flow Elements [Abstract]    
Cash paid for interest $ 624,896 $ 1,441,160
Cash paid for income taxes 1,386,955 157,346
Non-cash investing and financing activities:    
Accrued liabilities settled through the issuance of common stock and warrants 0 2,231,829
Exercise of stock options as reduction of notes payable, related party 2,500,000 0
Adjustment of goodwill 131,270 0
Assets acquired through capital leases 1,638,884 0
Acquisition of noncontrolling interest in Biohealth Medical Laboratory, Inc.   259,875
Acquisition of CollabRx 13,510,777 0
Conversions of preferred stock into common stock $ 25 $ 37,823,000